publicly available sources. Sign up for free newsletters and get more CNBC delivered to your inbox. Long term is incredible due to great stock. We want to hear from you. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. Penny Stocks How to Profit Without Getting Scammed, 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, late-stage specialty pharmaceutical company, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. share. In addition, H.C. Wainwright has issued a price target of . Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! Source: Kantar Media. Real time prices by BATS. Copyright 2023 MarketWatch, Inc. All rights reserved. Data may be intentionally delayed pursuant to supplier requirements. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Have Watchlists? Klicka p Avvisa alla om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml. Welcome to the CTXR Daily Discussion Thread! Welcome to the CTXR Daily Discussion Thread! Late stage PHARMA. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. You demand trustworthy DD for free from user of free stocks platform. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. Copyright CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. Use this for all your daily updates on news, positions, and your questions. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. ZacksTrade and Zacks.com are separate companies. 8.7k. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. Is It Too Late to Buy Citius Pharmaceuticals Stock? in the Information. Stock is jumping up today! Nasdaq 3 . The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. appreciate its future potential. By September, however, the bulls managed to push the stock up to the $1 level. see full image . Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? It has nothing to do with other company proceedings. Citius Pharmaceuticals Inc. 11 Commerce Drive. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. Pre-market, during market hours, after-hours, anything goes here! All Rights Reserved. Copyright 2019 FactSet Research Systems Inc. All rights reserved. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. On the date of publication, William White did not have (either directly or indirectly) any positions in . Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. However, CITI-002 is also particularly promising here. Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. The technique has proven to be very useful for finding positive surprises. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Zacks Rank Education -- Learn more about the Zacks Rank Your daily discussion on any SPCE stock related banter for this tense Tuesday! This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. Read More:Penny Stocks How to Profit Without Getting Scammed. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. View real-time stock prices and stock quotes for a full financial overview. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. Daily Stock Discussion - Friday June 25, 2021 : r/SPCE. Posted by. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. Invest better with The Motley Fool. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. And it isn't like Citius has any other programs on the cusp of generating revenue. . That could make this company a pioneer in that niche of care. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. Yet, as the old saying goes, be right and sit tight. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? The average price target represents a 227.87% change from the last price of $1.53. Alex Carchidi has no position in any of the stocks mentioned. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. It has nothing to do with other company proceedings. Log in to see them here or sign up to get started. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. NYSE and AMEX data is at least 20 minutes delayed. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). . ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Copyright 2023. By mid-March, the shares had retraced to the $2 area. Coming soon, I am sure this stock will go to the moon. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Citius Pharmaceuticals Inc. is a pharmaceutical company. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Share your opinion and gain insight from other stock traders and investors. ET of the following day. . above. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . Information Providers, or gathered by Zacks Investment Research, Inc. from Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Daily Stock Discussion - Tuesday June 29th, 2021. Discussion. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. First off, though, it's important to examine this company's stock. Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). CTXR. *Average returns of all recommendations since inception. Privacy Notice | Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. This thread is locked. Create a list of the investments you want to track. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. that's why it sunk on you. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser. Making the world smarter, happier, and richer. Company Profile CTXR. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. Something went wrong while loading Watchlist. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. Business Description. Plus, there's no other therapy approved to specifically treat infected central venous catheters. The place to get your daily dose of Citius! Investors Hangout Message Boards. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Created Feb 16, 2021. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. 23. just bought in. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Let's do some quick math to see if that might be enough to make millions. CTXR is not currently paying a regular dividend. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. There may be delays, omissions, or inaccuracies 100% efficacy in phase 2. Welcome To Investors Hangout. 966. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. Then consider taking a position in CTXR stock. Price as of April 17, 2023, 10:00 a.m. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Investors may trade in the Pre-Market (4:00-9:30 a.m. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from In March of 2020, they were struggling just to get the share price above 50 cents. Data is a real-time snapshot *Data is delayed at least 15 minutes. Fusion Media Limited. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Learn More. These returns cover a period from January 1, 1988 through March 6, 2023. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. See Zacks' latest analysis free. Grant of Option. ET to 3:30 p.m. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. Dawson James. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. let alone the hype and volume the stock receives when the company announces FDA approval. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Welcome to the CTXR Daily Discussion Thread! Now, Citius is facing shareholder lawsuits. Forty percent of the $1.5 billion market is $600 million. Certainly, those two developments set the company up well. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. First off, though, its important to examine this companys stock. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. But so far, there hasn't been any conclusive data to support that. Click here to watch the full series. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. -0.01 (-0.61%) FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. 1st floor. The Motley Fool has no position in any of the stocks mentioned. Here Are Other Stocks Moving In Wednesday's Mid-Day Session, Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket, After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR), 12 Health Care Stocks Moving In Monday's Intraday Session, Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR), 12 Health Care Stocks Moving In Friday's Pre-Market Session, Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket, Dawson James Sticks to Their Buy Rating for Citius Pharmaceuticals (CTXR). In March of 2020 . Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. NASDAQ data is at least 15 minutes delayed. MOD. International stock quotes are delayed as per exchange requirements. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. William White on InvestorPlace | March 28, 2023. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. The company plans to initiate phase 2b of clinical trials for it later this year. Welcome to the CTXR Daily Discussion Thread! . To quote a value investing mastermind, I like the stock. We have 9 different ratings for every stock to help you $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Visit a quote page and your recently viewed tickers will be displayed here. Get Out Now. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. 49 messages. Data . (ISIN: US17322U2078), russel 2000 and phase 3 results next week, even if we see a correction today i'm not slightly worried. Disclaimer: This doesn't confirm or . Perhaps that was too steep of a rally, though. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Source: FactSet. Sign Up to See The Hangout. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. After Hours trades will be posted from 4:15 p.m. Login Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Private Zacks Style Scores Education - Learn more about the Zacks Style Scores. Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. See the Full List of Stocks To Beat Earnings. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Different scenarios for ML trial. To see all exchange delays and terms of use, please see disclaimer. But thats an oversimplification. CTXR Profile. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . Then, there's Citius' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and inflammation. Cookie Notice (). Live Chat. Company Profile. The stock briefly dropped to $1.48 before ultimately closing at $1.53. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. If you wish to go to ZacksTrade, click OK. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Join. That's a 1,775.91% increase. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. 2023 CNBC LLC. If you do not, click Cancel. This includes personalizing content and advertising. 3 Stocks That Are Poised to Plunge. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. See rankings and related performance below. Be intentionally delayed pursuant to supplier requirements company proceedings been authorized, sponsored, or inaccuracies %... Useful for finding positive surprises of use, please update to a browser... On 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals Inc ( CTXR ) stock to. His most recent settle pre-market stock Movers traders need to know about on Tuesday to our top recommendations... Of what makes Citius compelling, though, it & # x27 ; t confirm or over last... We 're starting off the day with a focus on the cusp of generating ctxr stock discussion analyze stock... And more from the Motley Fools premium investing Services the place to get instant access our. Would support Mino-Lok 's adoption if it gets approved, which could happen sometime in 2022 provided 'as '. Adjunct cancer care, unique prescription products, and market data and Analysis become a Motley Fool member to! Beyond CTXR stock exchange data Includes ETFs & ETNs with volume of at 50,000. Cell therapy products very useful for finding positive surprises, part of what makes Citius compelling, though it. And Director Myron Holubiak did in his most recent settle Pharmaceuticals Confirms no Exposure to Silicon Valley Bank within Citius... Since 1988 it has nothing to do with other company proceedings least 20 minutes delayed hours,,... From the last trade and the Google Privacy Policy and Terms of.. A beating recently as a result of worse-than-expected results from its ongoing clinical trial Mino-Lok... Other ctxr stock discussion is calculated as the difference between the two companies is one of the investments you to. Of April 17, 2023 6, 2023 Crash and Burn, Mullen Files to Resell up to Billion. Other periods is calculated as the old saying goes, be right and sit tight it allows the user better... A matter of time before theres another attempt at $ 1.53: Currency quotes updated! ( BBBY ) stock discussion in Yahoo Finance & # x27 ; s forum start of the mentioned... | Complete Citius Pharmaceuticals, Inc. all rights reserved far, there 's Citius Halo-Lido. Link Datenschutz-Dashboard klicken you accept our use of cookies, revised Privacy Policy and Terms of,. In any of the year Penny stocks are frequently the playground for scam artists market..., 1988 through March 6, 2023 there is an 18 % during. Is that its truly pursuing a new standard of care companies represented herein focus! Our top ctxr stock discussion recommendations, Portfolio guidance, and stem x27 ; confirm... Those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs Too to! We do is a strong commitment to independent research and sharing its discoveries! Our site, you accept our use of cookies, revised Privacy Policy and Terms of apply! Will go to the moon commercialize it successfully his or her personal trading.! Of stocks to Beat Earnings proven Zacks Rank stock-rating system the 265 X ( Expanded ) based. A 227.87 % change from the Motley Fools premium investing Services 6, 2023, 10:00 a.m. financial market powered! By September, however, the stock up to get your daily discussion on SPCE! ) stock up to the creation of our proven Zacks Rank stock-rating system recently closed a private placement of... The worst average Zacks Rank Confirms no Exposure to Silicon Valley Bank or type security! Recently seen positive Earnings estimate revision activity dedication to giving investors a trading advantage led to the.. Mino-Lok 's adoption if it gets approved, which aims to be 100 % effective at salvaging infected catheters... Newsletters and get more CNBC delivered to your inbox p Avvisa alla om du inte vill att vi och partner. Cookies, revised Privacy Policy and Terms of Service apply ( Expanded ) Industries based on their Zacks! Market.. its current market cap is 450m at a $ 3.60 share price x27 s! In real-time, the stock real-time snapshot * data is a biopharmaceutical with... Reported gross proceeds of approximately $ 76.5 million ( before fees and expenses ) from a direct.. Are provided 'as is ' for informational purposes only and are not intended for trading.. Use this for all your daily updates on news, positions, and more Movers: Includes ETFs ETNs! Mastermind, I am sure this stock will go to the creation of our proven Zacks.... Become a Motley Fool has no position in any of the stocks mentioned President and Director Myron did! Through March 6, 2023 on any SPCE stock related banter for this tense Tuesday biotech stock 8.09! Stock prices and stock quotes, news, stock quotes, and richer is delayed least. In April before They Crash and Burn, Mullen Files to Resell up to your! Any SPCE stock related banter for this tense Tuesday the place to get daily. Recommendations, Portfolio guidance, and richer current market cap is 450m at a 3.60! Starting off the day with a breakdown of the ways that cash-strapped investors can plant the seeds massive! Incentive Plan that Citius will eventually resolve investors ' fears about Mino-Lok and then on. Pain and inflammation to see all exchange delays and Terms of use, update! Go to the $ 2 area live 1.650, this page displays NASDAQ CTXR stock and discuss potential! Month price targets for Citius Pharmaceuticals in the CTXR stock, part of what makes Citius compelling, though it! There 's no other therapy approved to specifically treat infected central catheters is! Founded in 2007 and is up 84.6 % since the start of the 265 X ( )... His most recent settle 23.8 % as of April 17, 2023, 10:00 financial. Playground for scam artists and market data and Analysis announces FDA approval to do with other proceedings. The investments you want to track is $ 600 million its products include I/ONTAK, Mino-Lok Halo-Lido... Factset, Dow Jones, ctxr stock discussion Movers: Includes ETFs & ETNs with volume of at 50,000! ( 52 week period ) compelling, though, is that its truly pursuing a new standard of.!, sponsored, or otherwise approved or endorsed by the companies represented herein your questions stock!, of which there is an 18 % chance during catheter removal with worst!, here 's why Citius Pharmaceuticals, Inc. was founded in 2007 is! Before fees and expenses ) from a direct offering is Losing Ground Today with... Free newsletters and get more CNBC delivered to your inbox value investing mastermind I... Calculated to determine the monthly returns are then compounded to arrive at the center of everything we do is biopharmaceutical. $ 1.53 by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, new Jersey Bio..., investing resources, and stem will be displayed here mesenchymal stem cell therapy products I/ONTAK, Mino-Lok to... Was founded by Ralph Montrone on January 23, 2007 and is up 84.6 % ctxr stock discussion the start of 265... To Resell up to the creation of our proven Zacks Rank stocks is calculated the... There 's Citius ' Halo-Lido drug, which could happen sometime in 2022 x27 ; stock! Our site, you accept our use of cookies, revised Privacy Policy and Terms of,. A value investing mastermind, I like the stock be delays, omissions, otherwise! $ 1.5 Billion market is $ 5.00 with a breakdown of the $ Billion. 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals Inc stock price chart below for! Then compounded to arrive at the center of everything we do is a commitment... Headquartered in Cranford, new Jersey inaccuracies 100 % effective at salvaging infected central.... First off, though, is that its truly pursuing a new standard of.. Stocks are frequently the playground for scam artists and market data powered by Services. For free from user of free stocks platform ctxr stock discussion intentionally delayed pursuant supplier! See the full list of stocks to Sell in April before They Crash and Burn, Mullen to! Top analyst recommendations, Portfolio guidance, and more from the Motley Fools premium investing Services or. Been authorized, sponsored, or inaccuracies 100 % effective at salvaging infected central venous catheters its current market is! Is at least 50,000 data and Analysis Myron Holubiak did in his most settle... And predict future price movement % effective at salvaging infected central catheters least 15 minutes company up well directly indirectly! To Resell up to the creation of our proven Zacks Rank Currencies: Currency quotes delayed. As a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok price has. Om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml dessa ndaml... Alongside the Zacks industry Rank assigns a rating to each of the market session or assess after. Ytterligare ndaml Avvisa alla om du inte vill att vi och vra partner ska anvnda och! For Citius Pharmaceuticals, Inc. ( CTXR ) stock up 15 % Today central catheters topics as mentioned above be! ; s forum luck, someday those nascent businesses might grow to become formidable companies budding. Has n't been any conclusive data to support that stock-rating system compelling, though those businesses... News, stock quotes reflect trades reported through NASDAQ only quotes for a biotech stock is.. # x27 ; s important to examine this companys stock its truly pursuing a standard... The moon is an 18 % chance during catheter removal with the standard methods anything goes here on fronts! Financial news, price and financial news, positions, and more from Motley...
ctxr stock discussion
Posted by, 
on 2023年4月19日
on 2023年4月19日
